NA Selank amidate

Research Use Only. Not for Human Consumption.

NA Selank amidate is supplied by Nexus as a terminally modified heptapeptide for controlled in-vitro research workflows. The supplied chemistry record identifies the compound as an N-acetylated, C-terminal amidated Selank analog based on the TKPRPGP heptapeptide sequence, with the displayed sequence Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂. Nexus catalog data lists one available research size: 30mg under SKU NSK30 in the Cognitive & Nootropic category.

The available source data for this SKU is intentionally narrow. It provides a structural description, computed formula, computed molecular weight, physical form, storage guidance, and intended-use restriction. It does not provide a confirmed CAS number, purity value, batch number, COA attributes, retention time, mass-found value, or peer-reviewed citation list specific to this terminally modified analog. This page therefore avoids filling those gaps with assumptions.

Compound Overview

NA Selank amidate is described as a modified Selank analog intended for research workflows comparing terminally protected forms against parent Selank. The source chemistry record identifies the base sequence as TKPRPGP and the displayed terminally modified sequence as Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂. The N-terminal acetyl group and C-terminal amide distinguish this material from an unmodified TKPRPGP sequence and make terminal-state confirmation an important part of identity review.

The compound is classified in the supplied data as a terminally modified heptapeptide. Its catalog placement is Cognitive & Nootropic, but the supplied record does not provide biological outcome claims, therapeutic claims, dosing guidance, clinical-use claims, or disease-context claims. Nexus presents this material strictly as an in-vitro research compound for qualified laboratory settings.

Research Background & Published Literature

The supplied research background is limited to a chemistry-focused caution: N-acetyl and C-terminal amidate modifications should be verified on the final COA, and parent Selank chemistry should not be copied directly to this modified SKU. That distinction is material because the source record treats NA Selank amidate as a terminally protected analog rather than as a direct substitute for parent Selank documentation.

No peer-reviewed citations specific to NA Selank amidate were provided in the supplied dataset. The source list includes a vendor/reference category for NA Selank amidate and a Bachem peptide molecular-weight calculation reference, but it does not include a publication set establishing exact experimental mechanisms, biological endpoints, validated assay conditions, or terminal-modification-specific findings for this SKU. Researchers should therefore treat this product page as a factual catalog and chemistry summary, not as a literature review.

• Research positioning: Modified Selank analog for workflows comparing terminally protected forms against parent Selank.
• Structural caution: Parent Selank chemistry should not be copied directly to this modified SKU.
• Verification caution: The N-acetyl and C-terminal amidate state should be confirmed by supplier COA/MS documentation.
• Literature limitation: No peer-reviewed citations specific to this exact analog were included in the supplied research data.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Zozulia et al. (2008) — Zh Nevrol Psikhiatr Im S S Korsakova
• Filatova et al. (2017) — Front Pharmacol
• Konstantinopolsky et al. (2022) — Bull Exp Biol Med

Storage, Handling & Stability Guidelines

Store lyophilized NA Selank amidate at -20°C, desiccated, and protected from light. The supplied storage guidance further states that, after reconstitution, laboratories should aliquot the material and avoid repeated freeze-thaw cycles. No validated post-reconstitution stability window, solvent system, concentration-specific hold time, or beyond-use period was provided in the source data.

• Keep lyophilized material sealed, dry, and light-protected during storage.
• Maintain -20°C storage conditions for unreconstituted material unless current lot documentation states otherwise.
• After reconstitution, divide material into aliquots appropriate to the laboratory workflow to reduce repeated freeze-thaw exposure.
• Do not infer a reconstitution solvent, working concentration, or post-reconstitution stability duration from this page; those parameters are not supplied in the research data.
• Use appropriate laboratory PPE and follow institutional chemical-handling procedures for peptide research reagents.

Lab Verification

Nexus maintains batch-level verification records through the Lab Verified archive. For peptide research materials, lab verification may include HPLC review for chromatographic profile and purity assessment, along with Mass Spectrometry (MS) review for molecular identity. For this specific NA Selank amidate record, no exact COA values, purity percentage, batch number, retention time, mass-found value, mass-expected value, or test date were provided in the supplied research data.

Because the source record flags terminal modification confirmation as a review point, identity verification should specifically confirm the N-acetyl and C-terminal amidate state. Until exact release documentation is available, Nexus should present the formula and molecular weight as computed chemistry-record values rather than finalized batch-specific COA results.